Ilaria Motta

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis et al. · New England Journal of Medicine · 2022 · 352 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

On tuberculosis and COVID-19 co-infection

Marina Tadolini, José-María García-García, F.–X. Blanc et al. · European Respiratory Journal · 2020 · 132 citations · Full text

Veterinary Medicine, Infectious Diseases, Internal Medicine +14

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis et al. · The Lancet Respiratory Medicine · 2023 · 96 citations · Full text

Pharmacy, Pharmacotherapy, Antimicrobial Pharmacotherapy +12

Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis

Lorenzo Guglielmetti, Uzma Khan, Gustavo E. Velásquez et al. · New England Journal of Medicine · 2025 · 76 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis

Catherine Berry, Philipp du Cros, Katherine Fielding et al. · Trials · 2022 · 66 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +9